Research Article

Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients

Jinrong Zhao, Yan Zhang, Wei Wang, Wei Zhang, and Dao-bin Zhou

Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

Correspondence should be addressed to Wei Zhang; vv1223@vip.sina.com and Dao-bin Zhou; zhoubdb@pumch.cn

Received 20 August 2022; Revised 8 October 2022; Accepted 8 November 2022; Published 17 November 2022

Copyright © 2022 Jinrong Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. To analyse the clinical features, outcomes, and risk factors of patients with diffuse large B-cell lymphoma (DLBCL) in China, with the aim to establish a new prognostic model based on risk factors. Methods. Clinical features and outcomes of 564 patients newly diagnosed with DLBCL from Jan 2009 to May 2017 were analyzed retrospectively. Variables were screened by LASSO regression and nomogram was constructed. Results. The 5-year overall survival (OS) of the cohort was 75%. The 5-year OS of patients differentiated by International Prognostic Index (IPI) score was 90% (score 0–2), 73% (score 3), and 51% (score 4–5), respectively. Age > 60, Eastern Cooperative Oncology Group (ECOG) > 1, Ann Arbor stage III-IV, bone marrow involvement, low level of albumin (ALB), and lymphatic/monocyte ratio (LMR) were independent predictors of OS. The predictive model was developed based on factors including age, bone marrow involvement, LMR, ALB, and ECOG scores. The predictive ability of the model (AUC, 0.77) was better than that of IPI (AUC, 0.74) and NCCN-IPI (AUC, 0.69). The 5-year OS of patients in the low-, intermediate-, and high-risk groups identified by the new predictive model was 89%, 70%, and 33%, respectively. Conclusions. The new prediction model had better predictive performance and could better identify high-risk patients.

1. Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25% of NHL cases [1]. The disease is aggressive and requires aggressive medical intervention after diagnosis. The International Prognostic Index (IPI) [2] has played an important role in determining the prognosis of patients with DLBCL over the past two decades. With the addition of rituximab to the CHOP or CHOP-like regimen, the prognosis of patients in each risk group according to IPI improved. New prognostic scoring systems, such as R-IPI [3] and NCCN-IPI [4], have emerged to better discriminate the survival of patients with DLBCL.

With the innovation of immunohistochemistry and molecular examination techniques and the optimization of treatment strategies, we need more accurate prognostic models to identify very high-risk DLBCL patients or biological heterogeneity to guide individualized treatment. The application of Lasso regression [5] facilitated the selection of variables, and the use of nomograms [6] proved to be of better predictive value. In this study, we analyzed the clinical characteristics of patients with DLBCL and explored the factors influencing survival, screened variables through Lasso regression, and constructed a nomogram to stratify the prognosis of patients with DLBCL.

2. Patients and Methods

2.1. Patients. From Jan 2009 to May 2017, a total of 564 patients newly diagnosed with DLBCL according to WHO classification [7] by three specialized pathologists were included. Patients who did not have complete clinical and immunohistochemical data or who were diagnosed but not treated in our hospital were excluded (n = 65). Because primary central nervous system lymphomas are highly...
heterogeneous entities, we also exclude them from our study (n = 41). Baseline data were collected such as gender, age, B symptoms, performance status, number of extranodal involvement, presence of bulky disease (≥7.5 cm), Ann Arbor stage, cell of origin, lactate dehydrogenase (LDH), albumin (Alb), white blood cell count (WBC), hemoglobin (HGB), platelet (PLT), absolute lymphocyte count (ALC), absolute monocyte count (AMC), the ratio of lymphocyte to monocyte (LMR), and D-dimer. All patients in the cohort were routinely examined by lumbar examination before treatment. Bone marrow examination was performed before treatment to determine whether there was bone marrow involvement, and the efficacy was assessed by whole-body computed tomography scan (CT) or positron emission tomography/computed tomography (PET-CT).

2.2. Treatment, Follow-Up, and Outcome. The first-line therapy for DLBCL patients was the R-CHOP or R-CHOP-like regimen [8]. Addition of intravenous methotrexate (1 g/m², four times) [9] injection was used as central prophylaxis in patients at central high risk. For elderly patients >70 years of age, we divided them into three groups: fit, unfit, and frail according to the comprehensive geriatric assessment (CGA) [10], and they were treated with R-CHOP, R-mini-CHOP [11], and R2 (rituximab 375 mg/m² on d1, lenalidomide 25 mg on day 1–14) regimens, respectively. Follow-up was conducted by making phone calls, consulting medical records, or the electronic follow-up system we run. 61 (10.8%) patients were lost to follow-up until the final follow-up period of May 1, 2022. Overall survival (OS) was calculated from the time of diagnosis to death for any cause or the last follow-up.

2.3. Model Foundation and Validation. 66.7% (n = 376) of the original dataset was randomly selected as a training cohort and the rest (n = 188) as a validation cohort. Univariate and multivariate Cox regression analyses were performed to screen potential variables associated with OS. The selected significant variables (P value <0.5) were then used in the least absolute shrinkage and selection operator (LASSO) regression algorithm, and then, a predictive nomogram was constructed. The area under receiver operating curve (AUC) is used to evaluate the performance of the model. According to the analysis results, calibration curves are drawn to determine whether the predicted and actual survival probabilities are consistent. The total score for each patient was assessed using nomogram in an externally validated cohort and used as an independent factor for Cox regression analysis.

2.4. Statistical Analysis. The survival of patients was analyzed by Kaplan–Meier survival curve, and differences between groups were compared by the log-rank test. GraphPad Prism 9.0 and R statistical software 4.1.3 (https://www.r-project.org/) were used to perform the statistical analyses. P value <0.05 was considered to be statistically different.

3. Results

3.1. Clinical Characteristics. The baseline clinical characteristics of the entire cohort are shown in Table 1. 282 (50.0%) patients included in this study were male. The median age of all patients was 58 years (range: 15–90). The age distribution at diagnosis is shown in Figure 1(a). More patients were non-GCB subtype (50.7%) and advanced stage (72.0%). Fewer patients had bulky disease (13.7%), bone marrow (12.6%), or CNS involvement (6.4%). The gastrointestinal tract (GIT) constituted the most common site of primary extranodal DLBCL, accounting for 15.8% (89/564) of DLBCL cases (9.2% stomach and 6.6% intestine). Patients with primary breast involvement rank second (14, 2.5%), followed by the thyroid gland (12, 2.1%), testis (11, 2.0%), female genital system (9, 1.6%), bone (9, 1.6%), and others. Figure 1(b) shows the site distribution of extranodal lymphomas. No significant difference in clinical characteristics was found between the training and validation cohorts (P > 0.05).

3.2. Outcome. At the last follow-up, 18.6% (105/564) of patients were lost to follow-up, 22.5% (127/564) of patients were dead. The 5-year OS of patients with DLBCL was 75% (Figure 2(a)). Patients with GCB subtype (Figure 1(b)), Ann Arbor stage I-II (Figure 2(c)), ECOG score 0-1 (Figure 2(d)), and fewer extranodal involvement sites (Figure 2(g)) had better clinical outcome. The overall survival of patients with bone marrow (Figure 2(e)) or CNS (Figure 2(f)) involvement was significantly lower than those without. Patients with lower Alb or LMR levels resulted in lower 5-year OS rate (59% vs. 82%, P < 0.0001; 67% vs. 81%, P = 0.0004) (Figures 2(h) and 2(i)).

3.3. Risk Factors. The univariate and multivariate analyses results for patients with DLBCL are presented in Table 2. On the basis of the univariate results, gender, age, ECOG, B symptom, Ann Arbor stage, IPI score, cell of origin, BM involvement, CNS involvement, extranodal site, LDH level, LMR, and Alb were significantly associated with survival. However, in the multivariate analysis, age > 60 (HR: 2.086, 95% CI: 1.371–3.175), ECOG > 1 (HR: 2.666, 95% CI: 1.790–3.970), Ann Arbor stage III-IV (HR: 1.857, 95% CI: 1.035–3.333), BM involvement (HR: 2.024, 95% CI: 1.413–2.898), low LMR (HR: 1.605, 95% CI: 1.128–2.283), and low Alb (HR: 1.548, 95% CI: 1.035–3.333) were independent risk factors of OS in patients with DLBCL.

3.4. Parameter Selection. A total of 16 candidate parameters (age, gender, cell of origin, Ki-67, bulky disease, BM involvement, CNS involvement, B symptom, LDH, D-dimer, Alb, LMR, ECOG, Ann Arbor stage, extranodal site, and HBsAg) in the training cohort were screened and verified using Lasso Cox regression (Figures 3(a) and 3(b)). Finally, several factors, age, BM involvement, LMR, Alb, and ECOG performance status, were independently associated with the prognosis of patients with DLBCL and were included in subsequent nomogram.
| Characteristics | All patients, n (%) | Training cohort, n (%) | Validation cohort, n (%) | P value<sup>a</sup> |
|----------------|--------------------|------------------------|--------------------------|------------------|
| **Total**      | 564                | 376                    | 188                      |                  |
| **Gender**     |                    |                        |                          |                  |
| Male           | 282 (50.0)         | 191 (50.8)             | 91 (48.4)                | 0.592            |
| Female         | 282 (50.0)         | 185 (49.2)             | 97 (51.6)                |                  |
| **Age**        |                    |                        |                          |                  |
| ≤60            | 320 (56.7)         | 208 (55.3)             | 112 (59.6)               | 0.336            |
| >60            | 244 (43.3)         | 168 (44.7)             | 76 (40.4)                |                  |
| **COO**        |                    |                        |                          |                  |
| GCB            | 278 (49.3)         | 177 (47.1)             | 101 (53.7)               | 0.137            |
| Non-GCB        | 286 (50.7)         | 199 (52.9)             | 87 (46.3)                |                  |
| **Ki-67 (%)**  |                    |                        |                          |                  |
| ≥90            | 135 (23.9)         | 87 (24.8)              | 48 (26.5)                | 0.530            |
| <90            | 429 (76.1)         | 289 (75.2)             | 140 (73.5)               |                  |
| **B symptoms** |                    |                        |                          |                  |
| Presence       | 289 (51.2)         | 190 (50.6)             | 99 (52.7)                | 0.634            |
| Absence        | 487 (86.3)         | 186 (49.4)             | 89 (47.3)                |                  |
| **ECOG**       |                    |                        |                          |                  |
| 0-1            | 288 (51.1)         | 190 (50.1)             | 88 (46.8)                | 0.810            |
| >1             | 276 (48.9)         | 186 (49.9)             | 90 (53.2)                |                  |
| **Bulky disease** |                |                        |                          |                  |
| Presence       | 77 (13.7)          | 48 (12.8)              | 29 (15.4)                | 0.386            |
| Absence        | 487 (86.3)         | 328 (87.2)             | 159 (84.6)               |                  |
| **Ann Arbor**  |                    |                        |                          |                  |
| I-II           | 158 (28.0)         | 103 (27.4)             | 55 (31.2)                | 0.643            |
| III-IV         | 406 (72.0)         | 273 (72.6)             | 133 (68.8)               |                  |
| **No. of extranodal sites** | | | | |
| 0-1            | 462 (81.9)         | 315 (83.8)             | 155 (87.1)               | 0.998            |
| >1             | 102 (18.1)         | 61 (16.2)              | 30 (12.9)                |                  |
| **BM involvement** |                |                        |                          |                  |
| Presence       | 71 (12.6)          | 44 (11.7)              | 27 (15.2)                | 0.369            |
| Absence        | 493 (87.4)         | 332 (88.3)             | 161 (84.8)               |                  |
| **CNS involvement** |            |                        |                          |                  |
| Presence       | 36 (6.4)           | 24 (7.2)               | 12 (6.8)                 | 1                |
| Absence        | 528 (93.6)         | 352 (92.8)             | 176 (93.2)               |                  |
| **LDH**        |                    |                        |                          |                  |
| Elevated       | 254 (45.0)         | 169 (44.9)             | 85 (48.3)                | 0.952            |
| Normal         | 310 (55.0)         | 207 (55.1)             | 103 (51.7)               |                  |
| **Alb**        |                    |                        |                          |                  |
| Low            | 167 (29.6)         | 109 (30.0)             | 58 (33.0)                | 0.648            |
| Normal         | 397 (70.4)         | 267 (70.0)             | 130 (67.0)               |                  |
| **LMR**        |                    |                        |                          |                  |
| Low<sup>b</sup>| 223 (39.5)         | 144 (38.3)             | 79 (44.9)                | 0.394            |
| High           | 341 (60.5)         | 232 (61.7)             | 109 (55.1)               |                  |
| **D-dimer**    |                    |                        |                          |                  |
| c > 0.87       | 332 (58.9)         | 223 (59.3)             | 109 (61.9)               | 0.762            |
| ≤0.87          | 232 (41.1)         | 153 (40.7)             | 79 (38.1)                |                  |
| **HBsAg**      |                    |                        |                          |                  |
| Positive       | 48 (8.5)           | 34 (9.0)               | 14 (8.0)                 | 0.522            |
| Negative       | 516 (91.5)         | 342 (91.0)             | 174 (92.0)               |                  |
| **IPI**        |                    |                        |                          |                  |
| 0-1            | 159 (28.2)         | 108 (28.7)             | 51 (27.1)                | 0.928            |
| 2              | 119 (21.1)         | 80 (21.3)              | 39 (20.7)                |                  |
| 3              | 125 (22.2)         | 84 (22.3)              | 41 (21.8)                |                  |
| 4-5            | 161 (28.5)         | 104 (27.7)             | 57 (30.3)                |                  |

LMR, lymphocyte-monocyte ratio; BM, bone marrow; CNS, central nervous system; COO, cell of origin; ECOG, Eastern Cooperative Oncology Group; Training cohort vs. validation cohort, \( P \) value was calculated by the Pearson Chi-square test, and \( P < 0.05 \) is regarded significant. \( \sigma < 2.5. \)
Figure 1: Distribution of age (a) and primary extranodal sites (b) in diffuse large B-cell lymphoma. CNS, central nervous system; FGS, female genital system.

Figure 2: Clinical outcomes for diffuse large B-cell lymphoma. Overall survival of the complete cohort (a) and in each subgroup according to pathological classification (b), Ann Arbor stage (c), ECOG performance status (d), bone marrow involvement (e), CNS involvement (f), extranodal site involvement (g), albumin levels (h), and LMR levels (i). CNS, central nervous system; LMR, lymphocyte-monocyte ratio; BM, bone marrow; EN-site, extranodal site. Statistical significance was tested with log-rank. P < 0.05 means a significant difference.
| Variables                        | Univariate, $P$ value | HR    | 95%           | Multivariate $P^*$ value |
|---------------------------------|-----------------------|-------|---------------|-------------------------|
| Male                            | 0.045                 | 0.151 |               |                         |
| Age > 60                        | <0.001                | 2.086 | 1.371–3.175   | <0.001                  |
| ECOG > 1                        | <0.001                | 2.666 | 1.790–3.970   | 0.001                   |
| With B symptom                  | <0.001                | 0.656 |               |                         |
| Ann Arbor stage III-IV          | <0.001                | 1.857 | 1.035–3.333   | 0.038                   |
| IPI > 2                         | <0.001                |       |               |                         |
| Non-GCB (reference GCB)         | 0.042                 | 0.393 |               |                         |
| Ki-67 > 90%                     | 0.251                 |       |               |                         |
| Bulky disease                   | 0.148                 |       |               |                         |
| BM involvement                  | <0.001                | 2.024 | 1.413–2.898   | <0.001                  |
| CNS involvement                 | 0.007                 |       |               | 0.381                   |
| No. of extranodal sites > 1     | 0.001                 |       |               | 0.194                   |
| Evaluated LDH                   | <0.001                |       |               | 0.083                   |
| Evaluated D-dimer               | 0.063                 |       |               | 0.873                   |
| Low LMR                         | 0.001                 | 1.605 | 1.128–2.283   | 0.015                   |
| Low ALB                         | <0.001                | 1.548 | 1.088–2.202   | 0.008                   |
| HbsAg positive                  | 0.808                 |       |               |                         |

ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell; CNS, central nervous system; LDH, lactate dehydrogenase; LMR, lymphocyte-monocyte ratio; $^*$ $P$ value was calculated by Cox regression, and $P < 0.05$ is regarded significant.

Figure 3: Continued.
3.5. Construction and Validation of the Predictive Nomogram.

The predictive model (Figure 3(c)) was constructed by 5 factors identified from the results of Lasso regression. In this model, ECOG performance status $\geq 2$ was assigned the highest score of 100, age $> 60$ years, bone marrow involvement, low levels of LMR, and low Alb was scored 86, 67, 58, and 28 points, respectively. The AUC for the nomogram was 0.77 (95% CI: 0.70–0.82), and the calibration curves of the nomogram showed great consistency between the predicted OS rates and actual observations outcome (Figures 3(d) and 3(e)).

3.6. Comparison with Current Prognostic Scoring Systems.

Nomograms showed better accuracy in predicting 5-year survival in cohorts compared to IPI, NCCN-IPI, NPI [12], and Kyoto-index [13] (Figures 4(a) and 4(b)). The AUC of the predictive model (0.77, 95% CI: 0.70–0.82) in the training cohort was higher than that of the IPI (0.74, 95% CI: 0.67–0.80), NCCN-IPI (0.69, 95% CI: 0.62–0.76), NPI (0.70, 95% CI: 0.63–0.76), and Kyoto-index (0.69, 95% CI: 0.62–0.76) ($p = 0.013$). Likewise, the AUC of IPI (0.72, 95% CI: 0.65–0.82) and NCCN-IPI (0.73, 95% CI: 0.65–0.82) in the validation cohort was lower than that of the predictive model.

We then classified all patients into low-, intermediate-, and high-risk groups based on OS scores generated by nomogram. The cutoff values were determined by X-tile software (Figure 5(a)). The 5-year OS of patients differentiated by International Prognostic Index (IPI) score was 99% (score 0–2), 73% (score 3), and 51% (score 4–5), respectively (Figure 5(c)). The 5-year OS of patients in the low-, intermediate-, and high-risk groups identified by the new predictive model was 89%, 70%, and 33%, respectively (Figure 5(b)).

To clearly demonstrate the relationship between IPI scores and the new model’s predictions in outcome of DLBCL patients, a Sankey diagram was constructed (Figure 6). We further categorized patients in the high-risk group (point 4-5) defined by the IPI score into subgroups of 117 patients in the nonhigh-risk group and 44 in the high-risk group by the new model. The baseline clinical characteristics of the two subgroups are shown in Table 3.

4. Discussion

To our knowledge, our cohort had the best clinical outcome among the reported studies with the same sample size of patients in general hospitals in China.

The median age of patients with DLBCL in our study was 58 years, which was consistent with the data reported by other research centers in Asia [14, 15], but lower than those reported in other continents [16, 17]. Compared with other studies [13, 18–27], especially in cancer hospitals in China [6, 12], our cohort had a higher proportion of patients with advanced stage and combined B symptoms, which indicated that patients in our center have a heavier burden of disease. Primary extranodal DLBCL can originate from almost any part of the body, and the most common site of involvement in our cohort was the gastrointestinal tract. In addition, the involvement of the mammary gland, thyroid gland, and testis also occupied a large portion, which was consistent with previously reported data [28–30].

Multicenter data showed that the 5-year OS of DLBCL is about 64% in the rituximab era [30–32], while the survival of our cohort was better. This may be due to the availability of more new drugs, improvements in supportive care, and appropriate adjustments in treatment regimens. Previous prediction models [2, 4] had shown that age, stage, ECOG PS, bone marrow involvement, and number of extranodal sites are momentous prognostic factors, and the data in our study were consistent. In addition, non-GCB [33] pathological subtype was a predictor of poor prognosis (5-year OS 73%).

Albumin levels are commonly used in lymphoma studies. Decreased albumin levels indicate the poor nutritional status of the patient or the consumption of the tumor. However, studies had shown that low Alb may be driven
more by proinflammatory status [34] or increased cytokine release [35] than by nutritional status. Biccler et al. [20] considered Alb as a predictor of poor clinical outcomes for patients with DLBCL. Similarly, our data suggested that patients with low Alb have significantly worse survival than other patients. In addition, McMillan et al. [36] considered albumin levels as a good predictor of disease progression. Patients with low albumin levels, especially older patients, were more prone to coinfection, which was also associated with a worse prognosis [37].

As an easily available biomarker, the role of LMR in predicting the survival of DLBCL had been increasingly emphasized. Absolute monocytes were positively associated with the number of tumor-associated macrophages, while the latter was associated with a worse prognosis of DLBCL [38]. Low absolute lymphocyte count suggested poor immune status and was associated with poor prognosis in patients with DLBCL. Therefore, lower LMR predicted worse clinical outcomes [39]. However, there is no uniform standard for the optimal cutoff value of LMR, and a meta-analysis of patients with DLBCL showed that LMR ranged from 1.6 to 4 [40]. Therefore, the critical point determined by ROC curve in our study is 2.5.

Survival of patients with DLBCL had greatly improved in the last 20 years, but we realized that survival in high-risk patients was still poor. We developed a new prediction model to better distinguish high-risk patients. Based on the original IPI and NCCN-IPI, we removed some variables and added Alb and LMR. After verification of internal and external data, the predictive model we developed proved to have good predictive performance. And this model had better predictive power than those of IPI and NCCN-IPI. High-risk patients differentiated according to our model had a worse prognosis.

The main limitation of our study was that it is a single-center retrospective study and its results may not be fully applicable to all patients with DLBCL. In addition, selection bias was difficult to avoid. The model we developed also needs to be validated by larger samples and external study cohorts.

In summary, we analyzed the clinical features of patients with DLBCL in our center and showed better survival. Then, we constructed a new model with better predictive performance by identifying prognostic risk factors, which may help clinicians to better predict clinical outcomes for patients in the rituximab era.
Figure 5: Cutoff values calculated by X-tile (a). Overall survival of patients with diffuse large B-cell lymphoma stratified by risk according to our new model (b) and IPI (c).

Figure 6: The relationship between the IPI score system and new predictive model shown by Sankey diagram. Panels on the left are grouped according to different IPI scores, and panels on the right are risk subscales based on the new model.
Data Availability

The data supporting the findings of this study are included within the article.

Table 3: Clinical characteristics of patients with DLBCL (IPI 4-5, n = 161).

| Characteristics | Non-high-riska, n (%) | High-riska, n (%) | P valueb |
|-----------------|-----------------------|-------------------|----------|
| Total           | 117                   | 44                |          |
| Gender          |                       |                   |          |
| Male            | 51 (43.6)             | 20 (45.5)         | 0.832    |
| Female          | 66 (56.4)             | 24 (54.5)         |          |
| Age             |                       |                   |          |
| ≤60             | 56 (47.9)             | 6 (13.6)          | <0.001   |
| >60             | 61 (52.1)             | 38 (86.4)         |          |
| COO             |                       |                   |          |
| GCB             | 56 (47.9)             | 15 (34.1)         | 0.117    |
| Non-GCB         | 61 (52.1)             | 29 (65.9)         |          |
| Ki-67 (%)       | ≥90                   | 26 (22.2)         | 9 (20.5) | 0.809    |
|                 | <90                   | 91 (77.8)         | 35 (79.5) |          |
| B symptoms      |                       |                   |          |
| Presence        | 87 (74.4)             | 38 (86.4)         | 0.103    |
| Absence         | 30 (25.6)             | 6 (13.6)          |          |
| ECOG            |                       |                   |          |
| 0-1             | 27 (23.1)             | 0 (0)             | <0.001   |
| >1              | 90 (79.9)             | 44 (100)          |          |
| Bulky disease   |                       |                   |          |
| Presence        | 15 (12.8)             | 3 (6.8)           | 0.403    |
| Absence         | 102 (87.2)            | 41 (93.2)         |          |
| Ann Arbor       |                       |                   |          |
| I-II            | 1 (0.8)               | 0 (0)             | 1        |
| III-IV          | 116 (99.2)            | 44 (100)          |          |
| No. of extranodal sites |       |                   |          |
| 0-1             | 78 (66.7)             | 23 (52.3)         | 0.092    |
| >1              | 39 (33.3)             | 21 (47.7)         |          |
| BM involvement  |                       |                   |          |
| Presence        | 18 (15.4)             | 25 (56.8)         | <0.001   |
| Absence         | 99 (84.6)             | 19 (43.2)         |          |
| CNS involvement |                       |                   |          |
| Presence        | 10 (8.5)              | 8 (18.2)          | 0.084    |
| Absence         | 107 (91.5)            | 36 (91.8)         |          |
| LDH             |                       |                   |          |
| Elevated        | 95 (81.2)             | 36 (81.8)         | 0.928    |
| Normal          | 22 (18.8)             | 8 (18.2)          |          |
| Alb             |                       |                   |          |
| Low             | 59 (50.5)             | 43 (97.7)         | <0.001   |
| Normal          | 58 (49.5)             | 1 (2.3)           |          |
| LMR             |                       |                   |          |
| Lowc            | 57 (48.7)             | 35 (79.5)         | <0.001   |
| High            | 60 (51.3)             | 9 (20.5)          |          |
| D-dimer         |                       |                   |          |
| >0.87           | 91 (77.8)             | 32 (72.7)         | 0.501    |
| ≤0.87           | 26 (22.2)             | 12 (27.3)         |          |
| HBsAg           |                       |                   |          |
| Positive        | 11 (9.4)              | 2 (4.5)           | 0.517    |
| Negative        | 106 (90.6)            | 42 (95.5)         |          |

LMR, lymphocyte-monocyte ratio; BM, bone marrow; CNS, central nervous system; COO, cell of origin; ECOG, Eastern Cooperative Oncology Group; *using our new model to distinguish prognostic subgroups. #non-high-risk vs. high-risk patients, P value was calculated by the Pearson Chi-square test or Fisher’s exact test, and P < 0.05 is regarded significant. ^<2.5.

Ethical Approval

All procedures followed were in accordance with the Helsinki Declaration. The study was approved by the Institutional Review Board of Peking Union Medical College Hospital.

Consent

Informed consent was obtained from all patients for being included in the study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Wei Zhang and Dao-bin Zhou conceptualized the study. Yan Zhang and Wei Wang performed data curation. Jinrong Zhao performed formal analysis, investigated, validated, and visualized the study, developed methodology, collected resources, developed software, and wrote the original draft of the manuscript. Dao-bin Zhou acquired fund and supervised the study. Wei Zhang reviewed and edited the article.

Acknowledgments

The authors thank the patients and their families and to Ms. Zhao Feiyan for her help in using the software. This work was supported by the National Natural Science Foundation of China (81970188).

References

[1] S. H. Swerdlow, E. Campo, S. A. Pileri et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, vol. 127, no. 20, pp. 2375–2390, 2016.
[2] International Non-Hodgkin’s Lymphoma Prognostic Factors Project, “A predictive model for aggressive non-Hodgkin’s lymphoma,” New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993.
[3] L. H. Sehn, B. Berry, M. Chhanabhai et al., “The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP,” Blood, vol. 109, no. 5, pp. 1857–1861, 2007.
[4] Z. Zhou, L. H. Sehn, A. W. Rademaker et al., “An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era,” Blood, vol. 123, no. 6, pp. 837–842, 2014.
[5] M. Pavlou, G. Ambler, S. Seaman, M. De Iorio, and R. Z. Omar, “Review and evaluation of penalised regression methods for risk prediction in low-dimensional data with few events,” Statistics in Medicine, vol. 35, no. 7, pp. 1159–1177, 2016.
[6] Y. Han, J. Yang, P. Liu et al., “Prognostic nomogram for overall survival in patients with diffuse large B-cell lymphoma,” The Oncologist, vol. 24, no. 11, pp. e1251–e1261, 2019.
[7] I. L. Polyatskin, A. S. Artemyeva, and Y. A. Krivolapov, “Revised WHO classification of tumors of hematopoietic and
lymphoid tissues, 2017 (4th edition): lymphoid tumors,”
Arkiv Patologii, vol. 81, no. 3, pp. 59–65, 2019.
[8] B. Coiffier, E. Lepage, J. Briere et al., “CHOP chemotherapy
plus rituximab compared with CHOP alone in elderly patients
with diffuse large-B-cell lymphoma,” New England Journal
of Medicine, vol. 346, no. 4, pp. 235–242, 2002.
[9] W. Wang, Y. Zhang, L. Zhang et al., “Intravenous methotrexate
at a dose of 1 g/m2 incorporated into RCHOP prevented
CNS relapse in high-risk DLBCL patients: a prospective, historic
controlled study,” American Journal of Hematology, vol. 95, no. 4,
pp. E80–e83, 2020.
[10] H. Wildiers, P. Heeren, M. Put et al., “International Society of
Geriatric Oncology consensus on geriatric assessment in older
patients with cancer,” Journal of Clinical Oncology, vol. 32,
no. 24, pp. 2595–2603, 2014.
[11] F. Peyrade, F. Jardin, C. Thieblemont et al., “Attenuated
immunochemotherapy regimen (R-miniCHOP) in elderly
patients older than 80 years with diffuse large-B-cell
lymphoma: a multicentre, single-arm, phase 2 trial,” The Lancet
Oncology, vol. 12, no. 5, pp. 460–468, 2011.
[12] J. Cai, X. Tian, S. Ma et al., “A nomogram prognostic index
for risk-stratification in diffuse large-B-cell lymphoma in the
rituximab era: a multi-institutional cohort study,” British
Journal of Cancer, vol. 125, no. 3, pp. 402–412, 2021.
[13] T. Kobayashi, J. Kuroda, Y. Yokota et al., “The Kyoto Prognostic
Index for patients with diffuse large-B-cell lymphoma in the
rituximab era,” Blood Cancer Journal, vol. 6, no. 1, p. e383,
2016.
[14] Q. P. Yang, W. Y. Zhang, J. B. Yu et al., “Subtype distribution
of lymphomas in Southwest China: analysis of 6,382 cases
using WHO classification in a single institution,” Diagnostic
Pathology, vol. 6, no. 1, p. 77, 2011.
[15] S. O. Yoon, C. Suh, D. H. Lee et al., “Distribution of lymphoid
neoplasms in the Republic of Korea: analysis of 5318 cases
according to the World Health Organization classification,”
American Journal of Hematology, vol. 85, no. 10, pp. 760–764,
2010.
[16] P. J. Shenoy, N. Malik, A. Nooka et al., “Racial differences in
the presentation and outcomes of diffuse large-B-cell
lymphoma in the United States,” Cancer, vol. 117, no. 11,
pp. 2530–2540, 2011.
[17] A. M. Perry, J. Diebold, B. N. Nathwani et al., “Non-Hodgkin
lymphoma in the developing world: review of 4539 cases from
the international non-Hodgkin lymphoma classification project,”
Haematologica, vol. 101, no. 10, pp. 1244–1250, 2016.
[18] H. Zhong, J. Chen, S. Cheng et al., “Prognostic nomogram
incorporating inflammatory cytokines for overall survival in
patients with aggressive non-Hodgkin’s lymphoma,” EBio-
Medicine, vol. 41, pp. 167–174, 2019.
[19] L. Ceriani, G. Gritti, L. Cascione et al., “SAKK38/07 study:
integration of baseline metabolic heterogeneity and metabolic
tumor volume in DLBCL prognostic model,” Blood Advances,
vol. 4, no. 6, pp. 1082–1092, 2020.
[20] J. L. Bicicler, S. Eloranta, P. de Nully Brown et al., “Optimizing
outcome prediction in diffuse large-B-cell lymphoma by use of
machine learning and nationwide lymphoma registries: a
nordic lymphoma group study,” JCO Clinical Informatics,
vol. 2, pp. 1–13, 2018.
[21] J. Roh, J. Jung, Y. Lee et al., “Risk stratification using multi-
tvariable fractional polynomials in diffuse large-B-cell
lymphoma,” Frontiers Oncology, vol. 10, p. 329, 2020.
[22] D. Antic, J. Jelicic, G. Trajkovic et al., “Is it possible to
improve prognostic value of NCCN-IPI in patients with diffuse large
B cell lymphoma? The prognostic significance of comorbid-
ities,” Annals of Hematology, vol. 97, no. 2, pp. 267–276, 2018.
[23] J. Kang, S. Yoon, and C. Suh, “Relevance of prognostic index
with β2-microglobulin for patients with diffuse large-B-cell
lymphoma in the rituximab era,” Blood Res, vol. 52, no. 4,
pp. 276–284, 2017.
[24] C. Montalbán, A. Díaz-López, I. Dlouhy et al., “Validation of
the NCCN-IPI for diffuse large-B-cell lymphoma (DLBCL): the
addition of β2-microglobulin yields a more accurate
GELTAMO-IPI,” British Journal of Haematology, vol. 176,
no. 6, pp. 918–928, 2017.
[25] Z. Y. Xu-Monette, L. Li, J. C. Byrd et al., “Assessment of
CD37 B-cell antigen and cell of origin significantly improves
risk prediction in diffuse large-B-cell lymphoma,” Blood,
vol. 128, no. 26, pp. 3083–3100, 2016.
[26] A. O. Gang, M. Pedersen, F. d’Amore et al., “A clinically based
prognostic index for diffuse large-B-cell lymphoma with a cut-off
at 70 years of age significantly improves prognostic
stratification: population-based analysis from the Danish
Lymphoma Registry,” Leukemia and Lymphoma, vol. 56,
no. 9, pp. 2556–2562, 2015.
[27] Y. Chen, S. Neelapu, L. Feng et al., “Prognostic significance of
baseline peripheral absolute neutrophil, monocyte and serum
β2-microglobulin level in patients with diffuse large-B-cell
lymphoma: a new prognostic model,” British Journal of
Haematology, vol. 175, no. 2, pp. 290–299, 2016.
[28] S. H. AlShemmari, R. M. Ameen, and K. P. Sajnani,
“Extranodal lymphoma: a comparative study,” Hematology,
vol. 13, no. 3, pp. 163–169, 2008.
[29] S. Reddy, E. Pellettiere, V. Saxena, and F. R. Hendrickson,
“Extranodal non-Hodgkin’s lymphoma,” Cancer, vol. 46,
no. 9, pp. 1925–1931, 1980.
[30] N. Epperla, J. L. Vaughn, M. Othus, A. Hallack, and
L. J. Costa, “Recent survival trends in diffuse large-B-cell
lymphoma--Have we made any progress beyond rituximab?,”
Cancer Medicine, vol. 9, no. 15, pp. 5519–5525, 2020.
[31] W. Liu, X. Ji, Y. Song et al., “Improving survival of 3760
patients with lymphoma: experience of an academic center
over two decades,” Cancer Medicine, vol. 9, no. 11,
pp. 3765–3774, 2020.
[32] Y. Shi, Y. Han, J. Yang et al., “Clinical features and outcomes
of diffuse large-B-cell lymphoma based on nodal or extranodal
primary sites of origin: analysis of 1,085 WHO classified cases
in a single institution in China,” Chinese Journal of Cancer
Research, vol. 31, no. 1, pp. 152–161, 2019.
[33] C. P. Hans, D. D. Weisenburger, T. C. Greiner,
R. D. Gascoyne, J. Delabie, and G. Ott, “Confirmation of the
molecular classification of diffuse large-B-cell lymphoma by
immunohistochemistry using a tissue microarray,” Blood,
vol. 103, no. 1, pp. 275–282, 2004.
[34] S. Dalila, J. Chavez, B. Little et al., “Serum albumin retains
independent prognostic significance in diffuse large-B-cell
lymphoma in the post-rituximab era,” Annals of Hematology,
vol. 93, no. 8, pp. 1305–1312, 2014.
[35] D. Gupta and C. G. Lis, “Pretreatment serum albumin as
a predictor of cancer survival: a systematic review of the
epidemiological literature,” Nutrition Journal, vol. 9, no. 1,
p. 69, 2010.
[36] D. C. McMillan, W. S. Watson, P. O’Gorman, T. Preston,
H. R. Scott, and C. S. McArdle, “Albumin concentrations are
primarily determined by the body cell mass and the systemic
inflammatory response in cancer patients with weight loss,”
Nutrition and Cancer, vol. 39, no. 2, pp. 210–213, 2001.
[37] Y. H. Jung, I. S. Woo, and C. W. Han, “Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review,” *Korean Journal of Internal Medicine (Korean Edition)*, vol. 30, no. 5, pp. 684–693, 2015.

[38] Y. L. Li, Z. H. Shi, X. Wang, K. S. Gu, and Z. M. Zhai, “Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count,” *BMC Cancer*, vol. 19, no. 1, p. 1049, 2019.

[39] W. K. Xia, Q. F. Lin, D. Shen, Z. L. Liu, J. Su, and W. D. Mao, “Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis,” *FEBS Open Bio*, vol. 6, pp. 558–565, 2016.

[40] F. Gao, J. Hu, J. Zhang, and Y. Xu, “Prognostic value of peripheral blood lymphocyte/monocyte ratio in lymphoma,” *Journal of Cancer*, vol. 12, pp. 3407–3417, 2021.